


Data Sheet

Product Name:	TPO agonist 1
Cat. No.:	CS-5711
CAS No.:	1033040-23-1
Molecular Formula:	C ₂₅ H ₂₂ N ₈ O ₂
Molecular Weight:	466.49
Target:	Thrombopoietin Receptor
Pathway:	Immunology/Inflammation
Solubility:	DMSO : ≥ 36 mg/mL (77.17 mM); H ₂ O : < 0.1 mg/mL (insoluble)



BIOLOGICAL ACTIVITY:

TPO agonist 1 is a **thrombopoietin (TPO)** agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia^[1]. IC₅₀ & Target: TPO receptor^[1] **In Vivo:** The thrombopoietin (TPO) receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes, and can increase platelet counts, decrease bleeding events and reduce the need for adjunctive or rescue treatments. The TPO receptor agonists are well-tolerated, though uncertainty remains regarding the risk of thromboembolism and bone marrow fibrosis^[2].

References:

[1]. Jerome Francis Hayes. Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics. 6 November 2008. WO2008134338A1.

[2]. Siegal D et al. Thrombopoietin receptor agonists in primary immune thrombocytopenia. et al. Semin Hematol. 2013 Jan;50 Suppl 1:S18-21

CAIndexNames:

1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone]

SMILES:

O=C(N(C1=CC=C(C)C(C)=C1)N=C/2C)C2=N\NC3=C(O)C(C4=CC=CC(C5=NN=NN5)=C4)=CC=C3

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA